Literature DB >> 23507279

In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection.

Yosuke Harada1, Katsunori Yanagihara, Koichi Yamada, Yohei Migiyama, Kentaro Nagaoka, Yoshitomo Morinaga, Shigeki Nakamura, Yoshifumi Imamura, Hiroo Hasegawa, Taiga Miyazaki, Koichi Izumikawa, Hiroshi Kakeya, Shigeru Kohno.   

Abstract

Daptomycin is inactivated by pulmonary surfactant, but its effectiveness in hematogenous pulmonary infection has been poorly studied. The potential therapeutic application was evaluated in a methicillin-resistant Staphylococcus aureus (MRSA) hematogenous pulmonary infection mouse model. Compared with control results, daptomycin improved survival (P < 0.001) and decreased the number of abscesses and bacteria in the lungs (P < 0.01). Daptomycin may be an effective therapeutic option for MRSA hematogenous pulmonary infection.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23507279      PMCID： PMC3716188          DOI： 10.1128/AAC.02331-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers.

Authors:  R Wise; T Gee; J M Andrews; B Dvorchik; G Marshall
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

3.  Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Nadia Z Haque; Mary Beth Perri; Susan Donabedian; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

4.  Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Authors:  A Louie; P Kaw; W Liu; N Jumbe; M H Miller; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads.

Authors:  T Sawai; K Tomono; K Yanagihara; Y Yamamoto; M Kaku; Y Hirakata; H Koga; T Tashiro; S Kohno
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

Review 6.  Special issues in the management of infective endocarditis caused by gram-positive cocci.

Authors:  Bruno Hoen
Journal:  Infect Dis Clin North Am       Date:  2002-06       Impact factor: 5.982

7.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

8.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.

Authors:  J R Woodworth; E H Nyhart; G L Brier; J D Wolny; H R Black
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis.

Authors:  Emine Alp; Suveyda Gozukucuk; Ozlem Canoz; Beyhan Kirmaci; Mehmet Doganay
Journal:  BMC Infect Dis       Date:  2004-10-18       Impact factor: 3.090
View more
  5 in total

1.  The Concern for Vancomycin Failure in the Treatment of Pediatric Staphylococcus aureus Disease.

Authors:  Isaac P Thomsen
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

2.  Efficacy of Tedizolid against Enterococci and Staphylococci, Including cfr + Strains, in a Mouse Peritonitis Model.

Authors:  Kavindra V Singh; Cesar A Arias; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Self-enhanced targeted delivery of a cell wall- and membrane-active antibiotics, daptomycin, against staphylococcal pneumonia.

Authors:  Hong Jiang; Meimei Xiong; Qiuyan Bi; Ying Wang; Chong Li
Journal:  Acta Pharm Sin B       Date:  2016-06-11       Impact factor: 11.413

4.  Hyperbaric Oxygen Therapy is Ineffective as an Adjuvant to Daptomycin with Rifampicin Treatment in a Murine Model of Staphylococcus aureus in Implant-Associated Osteomyelitis.

Authors:  Nis Pedersen Jørgensen; Kasper Hansen; Caroline Marie Andreasen; Michael Pedersen; Kurt Fuursted; Rikke L Meyer; Eskild Petersen
Journal:  Microorganisms       Date:  2017-04-25

5.  Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Nur Najihah Izzati Mat Rani; Xiang Yi Chen; Zahraa M Al-Zubaidi; Hanisah Azhari; Tzar Mohd Nizam Khaitir; Pei Yuen Ng; Fhataheya Buang; Geok Chin Tan; Yin Ping Wong; Mazlina Mohd Said; Adeel Masood Butt; Azmy A Hamid; Mohd Cairul Iqbal Mohd Amin
Journal:  Asian J Pharm Sci       Date:  2021-12-24       Impact factor: 6.598
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.